- Trials with a EudraCT protocol (146)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (28)
146 result(s) found for: Borg.
Displaying page 1 of 8.
EudraCT Number: 2022-004166-37 | Sponsor Protocol Number: 100424 | Start Date*: 2023-05-02 |
Sponsor Name:Division of Thoracic and Hyperbaric Surgery, Medical University Graz | ||
Full Title: Hyperbaric oxygenation for patients with orthostatic dysregulation (postural orthostatic tachycardia) in Long- COVID. Prospectively randomized cross- over study. | ||
Medical condition: Multiorgan symptoms after COVID-19 infection (Long COVID) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2016-003672-47 | Sponsor Protocol Number: CCD-01535BD1-01 | Start Date*: 2016-12-20 | |||||||||||
Sponsor Name:Chiesi Farmaceutici S.p.A. | |||||||||||||
Full Title: A single dose, randomised, double blind, double dummy, placebo controlled, 3-way crossover clinical study, comparing the onset of relief from methacholine-induced bronchoconstriction with CHF1535 1... | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002950-56 | Sponsor Protocol Number: AC-055E201 | Start Date*: 2014-02-20 | |||||||||||
Sponsor Name:Actelion Pharmaceuticals Ltd. | |||||||||||||
Full Title: Prospective, randomized, placebo-controlled, double-blind, multicenter, parallel-group, 24-week study to assess the efficacy, safety and tolerability of macitentan in subjects with inoperable chron... | |||||||||||||
Medical condition: Inoperable chronic thromboembolic pulmonary hypertension (CTEPH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) DE (Completed) AT (Completed) BE (Completed) GB (Completed) HU (Completed) NL (Completed) LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-009366-13 | Sponsor Protocol Number: TDE-PH-308 | Start Date*: 2009-09-02 | |||||||||||
Sponsor Name:United Therapeutics Corporation | |||||||||||||
Full Title: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hyp... | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) NL (Completed) BE (Completed) AT (Completed) DE (Completed) ES (Completed) SE (Completed) PT (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000097-26 | Sponsor Protocol Number: TDE-PH-310 | Start Date*: 2012-11-06 | |||||||||||
Sponsor Name:United Therapeutics Corporation | |||||||||||||
Full Title: A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects with Pulmonary Arterial Hypertension Receiving Background Oral... | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) AT (Completed) NL (Completed) IT (Completed) SE (Completed) BE (Completed) DK (Completed) GR (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003473-17 | Sponsor Protocol Number: CC-90001-IPF-001 | Start Date*: 2017-09-14 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A Phase 2, 24-Week Randomized, Double-blind, Placebo-Controlled Multicenter Study, With an 80-Week Active Treatment Extension, to Evaluate the Efficacy and Safety of CC-90001 in Subjects with Idiop... | |||||||||||||
Medical condition: IDIOPATHIC PULMONARY FIBROSIS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006718-13 | Sponsor Protocol Number: R0452 | Start Date*: 2007-10-11 | |||||||||||
Sponsor Name:Hull and East Yorkshire NHS Trust | |||||||||||||
Full Title: Opioids in the management of breathlessness in chronic heart failure | |||||||||||||
Medical condition: Patients known to the Academic Unit of Cardiology that have symptomatic chronic heart failure (New York Heart Association grading 3-4) despite maximal medical treatment. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000473-12 | Sponsor Protocol Number: ULT01 | Start Date*: 2015-10-12 |
Sponsor Name:UMCG | ||
Full Title: The effectiveness of single dose Ultibro Breezhaler (indacaterol/glycopyrronium) by sd-DPI versus ipratropium/salbutamol by nebulizer in improving FEV1 and dyspnea during stable state of COPD | ||
Medical condition: COPD, chronic obstructive pulmonary disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-002949-32 | Sponsor Protocol Number: SPHERE-HF | Start Date*: 2017-03-22 |
Sponsor Name:Fundació Clínic per la recerca Biomédica [...] | ||
Full Title: β3 adrenergic agoniSt treatment in chronic Pulmonary HypERtEnsion secondary to heart failure: a randomized placebo-controlled phase 2 clinical trial | ||
Medical condition: Pulmonary Hypertension secondary to heart failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2020-002482-34 | Sponsor Protocol Number: GAM10-10 | Start Date*: 2020-05-21 |
Sponsor Name:Octapharma USA | ||
Full Title: Efficacy and safety of Octagam 10% therapy in COVID-19 patients with severe disease progression | ||
Medical condition: COVID-19 | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2018-000050-22 | Sponsor Protocol Number: SEGCG18-01 | Start Date*: 2018-04-24 | |||||||||||
Sponsor Name:Skåne University Hospital, Department of Oncology | |||||||||||||
Full Title: Irinotecan-based triplet (FOLFOXIRI) as perioperative treatment in resectable gastric and gastroesophageal junction adenocarcinoma. | |||||||||||||
Medical condition: Resectabel gastric and gastroesophageal junction adenocarcinoma. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000843-33 | Sponsor Protocol Number: FERMIN | Start Date*: 2021-04-23 | |||||||||||||||||||||
Sponsor Name:Hellenic Institute for the Study of Sepsis | |||||||||||||||||||||||
Full Title: Fenofibrate as a Metabolic Intervention for Coronavirus Disease 2019 (COVID-19): A randomized controlled trial (FERMIN trial) | |||||||||||||||||||||||
Medical condition: Coronavirus disease-19 | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GR (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002484-99 | Sponsor Protocol Number: 2006 | Start Date*: 2007-01-10 |
Sponsor Name:South Devon Health Care NHS Foundation Trust | ||
Full Title: The Use of Nebulised Magnesium Sulphate in Exacerbations of Chronic Obstructive Pulmonary Disease (COPD) | ||
Medical condition: We propose a study to examine whether adjuvant magnesium therapy administered via nebuliser is effective in the management of patients with acute exacerbations of COPD. The findings should help to ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2004-004620-12 | Sponsor Protocol Number: dyspnoea1 | Start Date*: 2005-01-14 |
Sponsor Name:Royal Marsden Hospital | ||
Full Title: Assessment of normal release morphine in the management of dyspnoea | ||
Medical condition: Breathlessness of any cause in cancer patients are identified and treated with normal release morphine which has been shown to be both effective and safe.The idea of the trial is to see if there wi... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2008-006833-29 | Sponsor Protocol Number: BPS-MR-PAH-202Amendment1Ireland | Start Date*: 2009-06-29 | |||||||||||
Sponsor Name:Lung LLC | |||||||||||||
Full Title: An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004624-21 | Sponsor Protocol Number: AC-055-404 | Start Date*: 2015-04-13 | |||||||||||
Sponsor Name:ACTELION Pharmaceuticals Ltd. | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, prospective, multicenter, parallel group study to assess the safety and efficacy of macitentan in patients with portopulmonary hypertension | |||||||||||||
Medical condition: Portopulmonary hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) CZ (Completed) ES (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000153-31 | Sponsor Protocol Number: AIR001-CS06 | Start Date*: 2013-01-22 |
Sponsor Name:Aires Pharmaceuticals, Inc | ||
Full Title: A Phase 2, Multi-Center, Open-Label study to evaluate the intermediate/long term safety and efficacy of AIR001 in subjects with WHO Group I Pulmonary Arterial Hypertension | ||
Medical condition: Pulmonary Arterial Hypertension | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) DE (Completed) PL (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2009-014453-32 | Sponsor Protocol Number: BPS-MR-PAH-204,Amdt2US,BEL,RO | Start Date*: 2010-01-11 | |||||||||||
Sponsor Name:Lung LLC | |||||||||||||
Full Title: An open-label extension of BPS-MR-PAH-203 in pulmonary arterial hypertension (PAH) patients | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) IE (Completed) DE (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003335-33 | Sponsor Protocol Number: AC-055-305 | Start Date*: 2013-02-27 | |||||||||||
Sponsor Name:Actelion Pharmaceuticals Ltd. | |||||||||||||
Full Title: A multi-center, double-blind, randomized, placebo-controlled, parallel-group, Phase 3 study to evaluate the effects of macitentan on exercise capacity in subjects with Eisenmenger Syndrome. | |||||||||||||
Medical condition: Eisenmenger Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) BG (Completed) BE (Completed) DE (Completed) PT (Completed) NL (Completed) AT (Completed) ES (Completed) HU (Completed) CZ (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000895-27 | Sponsor Protocol Number: IIBSP-OXI-2017-18 | Start Date*: 2017-07-21 |
Sponsor Name:Institut de Recerca Hospital de la Santa Creu i Sant Pau | ||
Full Title: Can high-flow oxygen optimize the benefits of Pulmonary Rehabilitation in patients with Diffuse Interstitial LungDisease (ILD) with oxygen desaturation during effort? | ||
Medical condition: Diffuse Interstitial LungDisease (ILD) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
